796 related articles for article (PubMed ID: 26386686)
61. The safety of biological pharmacotherapy for the treatment of ulcerative colitis.
Fiorino G; Bonovas S; Cicerone C; Allocca M; Furfaro F; Correale C; Danese S
Expert Opin Drug Saf; 2017 Apr; 16(4):437-443. PubMed ID: 28279079
[TBL] [Abstract][Full Text] [Related]
62. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis.
Colombel JF; Ordás I; Ullman T; Rutgeerts P; Chai A; O'Byrne S; Lu TT; Panés J
Gastroenterology; 2016 Feb; 150(2):389-95.e3. PubMed ID: 26526713
[TBL] [Abstract][Full Text] [Related]
63. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
64. Vedolizumab for the treatment of ulcerative colitis.
Rietdijk ST; D'Haens GR
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046
[TBL] [Abstract][Full Text] [Related]
65. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
[TBL] [Abstract][Full Text] [Related]
66. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis.
Farkas K; Molnár T; Szepes Z
Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):695-702. PubMed ID: 24738535
[TBL] [Abstract][Full Text] [Related]
67. A fulminant colitis index greater or equal to 8 is not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks.
Baudet A; Colombel JF; Cortot A; Dupas JL; Brazier F; Savoye G; Lerebours E; Justum AM; Reimund JM
Gastroenterol Clin Biol; 2010 Nov; 34(11):612-7. PubMed ID: 20832218
[TBL] [Abstract][Full Text] [Related]
68. Ulcerative Colitis in Adults: A Review.
Gros B; Kaplan GG
JAMA; 2023 Sep; 330(10):951-965. PubMed ID: 37698559
[TBL] [Abstract][Full Text] [Related]
69. Biological agents for ulcerative colitis: hypes and hopes.
Danese S; Angelucci E; Malesci A; Caprilli R
Med Res Rev; 2008 Mar; 28(2):201-18. PubMed ID: 17464967
[TBL] [Abstract][Full Text] [Related]
70. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting.
Afzali A; Ogden K; Friedman ML; Chao J; Wang A
J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566
[TBL] [Abstract][Full Text] [Related]
71. Editorial: Is vedolizumab the preferred biologic therapy for biologic-naïve patients with ulcerative colitis?
Yamamoto T
Aliment Pharmacol Ther; 2023 Sep; 58(5):546-547. PubMed ID: 37559519
[No Abstract] [Full Text] [Related]
72. Up-to-date surgery for ulcerative colitis in the era of biologics.
Yamamoto T; Carvello M; Lightner AL; Spinelli A; Kotze PG
Expert Opin Biol Ther; 2020 Apr; 20(4):391-398. PubMed ID: 31948294
[No Abstract] [Full Text] [Related]
73. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
[TBL] [Abstract][Full Text] [Related]
74. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus.
Amiot A; Bouguen G; Bonnaud G; Bouhnik Y; Hagege H; Peyrin-Biroulet L;
Dig Liver Dis; 2021 Jan; 53(1):35-43. PubMed ID: 33160886
[TBL] [Abstract][Full Text] [Related]
75. An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis.
Ashat D; Jain A; Weaver KN; Long MD; Herfarth HH; Barnes EL
Dig Dis Sci; 2022 Dec; 67(12):5439-5443. PubMed ID: 36125593
[No Abstract] [Full Text] [Related]
76. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
[TBL] [Abstract][Full Text] [Related]
77. Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.
Abbenante D; Merli Y; Misciali C; Sacchelli L; Bardazzi F
Australas J Dermatol; 2022 Feb; 63(1):131-132. PubMed ID: 34817061
[No Abstract] [Full Text] [Related]
78. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
Restellini S; Khanna R; Afif W
Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
[TBL] [Abstract][Full Text] [Related]
79. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
Zoet ID; de Boer NK; de Meij TG
J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
[No Abstract] [Full Text] [Related]
80. Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis.
Kisiel JB; Konijeti GG; Piscitello AJ; Chandra T; Goss TF; Ahlquist DA; Farraye FA; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1778-1787.e8. PubMed ID: 27464589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
